Last reviewed · How we verify
NCT06024356
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer
trial testing Thymalfasin in Colorectal Neoplasms in 26 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Beijing Friendship Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 26 |
| Start date | 20 September 2023 |
| Primary completion | 31 December 2023 |
| Estimated completion | 30 March 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Thymalfasin (THYMALFASIN) — full drug profile →
Conditions studied
- Colorectal Neoplasms — all drugs for Colorectal Neoplasms →
Sponsor
Beijing Friendship Hospital
Who can join
18 and older, any sex, with Colorectal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is a single-center, retrospective, controlled study to investigate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin for locally advanced mid-low rectal cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06024356
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Thymalfasin
Trials testing the same drug.
- NCT04428008 — Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients · Phase 2 · completed
- NCT04487444 — Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection · Phase 2 · terminated
Other recruiting trials for Colorectal Neoplasms
Currently open trials in the same condition.
- NCT06983639 — Randomized Trial Comparing Fecal Testing (FIT) to Colonoscopy for Post-polypectomy Surveillance · NA · recruiting
- NCT07222800 — Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult · Phase 3 · recruiting
- NCT07239479 — DEXDES Trial: Dexmedetomidine-Desflurane Combination in Laparoscopic Colectomy · NA · recruiting
- NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
- NCT07257653 — The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line · Phase 2 · recruiting
Other Beijing Friendship Hospital trials
Trials by the same sponsor.
- NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
- NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
- NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
- NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06024356 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
- Last refreshed: 6 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06024356.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing